PHARM

Pharming announced positive topline Phase II data for leniolisib in primary immunodeficiencies…

Watch for full ESID 2026 presentation and Q4 2026 CVID Phase II topline results, which will determine registrational path for broader CVID indication.

FDA approved Pharming's Joenja (leniolisib) for children aged 4-11 with APDS, expanding the label…

Monitor commercial uptake of the new pediatric doses and the pending sNDA decision for lower-weight children (13kg to <27kg). The label expansion incrementally increases Joenja's total addressable…

Pharming Group announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients…

The launch in Japan opens a new revenue stream for Joenja, particularly in the pediatric segment (ages 4-11) where it is first-to-market globally. Monitor future quarterly filings for initial Japan…

Pharming Group reported Q2 2026 total revenues of $90.2M, down 3% YoY, with RUCONEST declining 10%…

The revenue guidance cut and sharp profitability decline signal near-term headwinds for PHARM. Monitor Q3 RUCONEST stabilization and Joenja growth trajectory, as well as the leniolisib CVID data…